<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62332">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02294461</url>
  </required_header>
  <id_info>
    <org_study_id>9785-CL-0232</org_study_id>
    <nct_id>NCT02294461</nct_id>
  </id_info>
  <brief_title>An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Patients</brief_title>
  <official_title>Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naïve Subjects With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study is to assess the effect of enzalutamide on time to Prostate Specific
      Antigen (PSA) progression as compared to placebo in chemotherapy naïve subjects with
      progressive metastatic prostate cancer who have failed androgen deprivation therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multinational Phase 3, randomized, double-blind, placebo-controlled efficacy
      and safety study of oral enzalutamide (formerly MDV3100) in asymptomatic or mildly
      symptomatic subjects with progressive metastatic prostate cancer who have disease
      progression despite androgen deprivation therapy. Subjects must not have been previously
      treated with cytotoxic chemotherapy. Approximately 30 Chinese subjects will be allocated to
      the PK cohort. The subjects in PK cohort will be requested to be hospitalized from one day
      before the date of randomization to at least the completion of all the assessments planned
      on Day 3. All subjects in PK cohort will undergo blood sampling for PK analysis of unchanged
      enzalutamide and its major metabolites regardless of treatment arm.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Prostate-specific Antigen Progression (PSA)</measure>
    <time_frame>Up to 16.3 months</time_frame>
    <description>Prostate Specific Antigen (PSA) progression is defined according to the consensus guidelines of the Prostate Cancer Clinical Trials Working Group 2 (PCWG2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of radiographic progression free survival</measure>
    <time_frame>up to 41 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Survival</measure>
    <time_frame>up to 41 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, laboratory tests, vital signs, physical examinations and 12-lead ECG.</measure>
    <time_frame>up to 41 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Analysis of enzalutamide and major metabolites (tmax)</measure>
    <time_frame>Day 1, Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Analysis of enzalutamide and major metabolites (Cmax)</measure>
    <time_frame>Day 1, Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Analysis of enzalutamide and major metabolites (AUC)</measure>
    <time_frame>Day 1, Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Analysis of enzalutamide and major metabolites (Cmin)</measure>
    <time_frame>Day 2, 3, 8, 22, 29, 43, 57, 85, 86, 113, 141 and 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of enzalutamide</measure>
    <time_frame>Day 85</time_frame>
    <description>CL/F = Dose / AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak-trough ratio (PTR) of enzalutamide and major metabolites</measure>
    <time_frame>Day 85</time_frame>
    <description>Peak-trough ratio (PTR) = Cmax/Cmin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Progressive Metastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>enzalutamide arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enzalutamide</intervention_name>
    <description>oral</description>
    <arm_group_label>enzalutamide arm</arm_group_label>
    <other_name>Xtandi</other_name>
    <other_name>MDV3100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate without neuroendocrine
             differentiation or small cell features

          -  Ongoing androgen deprivation therapy with a GnRH analogue or bilateral orchiectomy

          -  Progressive disease despite androgen deprivation therapy as defined by rising PSA
             levels or progressive soft tissue or bone disease

          -  No prior treatment with cytotoxic chemotherapy

          -  Asymptomatic or mildly symptomatic from prostate cancer

        Exclusion Criteria:

          -  Severe concurrent disease, infection, or co-morbidity that, in the judgment of the
             Investigator, would make the patient inappropriate for enrollment

          -  Known or suspected brain metastasis or active leptomeningeal disease

          -  History of another malignancy within the previous 5 years other than curatively
             treated non-melanomatous skin cancer

          -  History of seizure including febrile seizure or any condition that may predispose to
             seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss
             of consciousness requiring hospitalization).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chungbuk</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>September 1, 2016</lastchanged_date>
  <firstreceived_date>November 13, 2014</firstreceived_date>
  <firstreceived_results_disposition_date>September 1, 2016</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enzalutamide</keyword>
  <keyword>Androgen receptor</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Xtandi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
